Treatment of HER2-Negative EBC

CE / CME

Expert Review of Treatment for HER2-Negative Early Breast Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 31, 2023

Expiration: August 30, 2024

Kevin Kalinsky
Kevin Kalinsky, MD, MS

Activity

Progress
1
Course Completed

Key Takeaways

  • Recent trials have altered the treatment landscape for patients with EBC.
    • Adjuvant abemaciclib and olaparib are options for eligible patients with HR-positive/HER2-negative EBC.
    • In addition to (neo)adjuvant pembrolizumab for early-stage TNBC, adjuvant capecitabine and olaparib are options for eligible patients.  
  • ADCs, SERDs, and ICIs are currently being evaluated in both the neoadjuvant and adjuvant settings, as single agents and in various combinations.
  • It is critical that biomarker and genomic testing be performed in all eligible patients, regardless of race or ethnicity.
  • All healthcare professionals should work to increase diversity in clinical trial enrollment.